Literature DB >> 25240203

Inhibition of p300 suppresses growth of breast cancer. Role of p300 subcellular localization.

María E Fermento1, Norberto A Gandini2, Débora G Salomón3, María J Ferronato4, Cristian A Vitale5, Julián Arévalo6, Alejandro López Romero7, Myriam Nuñez8, Manfred Jung9, María M Facchinetti10, Alejandro C Curino11.   

Abstract

There is evidence that p300, a transcriptional co-factor and a lysine acetyl-transferase, could play a role both as an oncoprotein and as a tumor suppressor, although little is known regarding its role in breast cancer (BC). First we investigated the role p300 has on BC by performing pharmacological inhibition of p300 acetyl-transferase function and analyzing the effects on cell count, migration and invasion in LM3 murine breast cancer cell line and on tumor progression in a syngeneic murine model. We subsequently studied p300 protein expression in human BC biopsies and evaluated its correlation with clinical and histopathological parameters of the patients. We observed that inhibition of p300 induced apoptosis and reduced migration and invasion in cultured LM3 cells. Furthermore, a significant reduction in tumor burden, number of lung metastases and number of tumors invading the abdominal cavity was observed in a syngeneic tumor model of LM3 following treatment with the p300 inhibitor. This reduction in tumor burden was accompanied by a decrease in the mitotic index and Ki-67 levels and an increase in Bax expression. Moreover, the analysis of p300 expression in human BC samples showed that p300 immunoreactivity is significantly higher in the cancerous tissues than in the non-malignant mammary tissues and in the histologically normal adjacent tissues. Interestingly, p300 was observed in the cytoplasm, and the rate of cytoplasmic p300 was higher in BC than in non-tumor tissues. Importantly, we found that cytoplasmic localization of p300 is associated with a longer overall survival time of the patients. In conclusion, we demonstrated that inhibition of the acetylase function of p300 reduces both cell count and invasion in LM3 cells, and decreases tumor progression in the animal model. In addition, we show that the presence of p300 in the cytoplasm correlates with increased survival of patients suggesting that its nuclear localization is necessary for the pro-tumoral effects.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Animal model; Breast cancer; Cell line; Human biopsies; p300

Mesh:

Substances:

Year:  2014        PMID: 25240203     DOI: 10.1016/j.yexmp.2014.09.019

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  14 in total

1.  Germline or inducible knockout of p300 or CBP in skeletal muscle does not alter insulin sensitivity.

Authors:  Vitor F Martins; Jessica R Dent; Kristoffer Svensson; Shahriar Tahvilian; Maedha Begur; Shivani Lakkaraju; Elisa H Buckner; Samuel A LaBarge; Byron Hetrick; Carrie E McCurdy; Simon Schenk
Journal:  Am J Physiol Endocrinol Metab       Date:  2019-03-19       Impact factor: 4.310

Review 2.  The role of histone deacetylase 3 in breast cancer.

Authors:  Rezgar Rahbari; Yousef Rasmi; Mohammad Hassan Khadem-Ansari; Mohammad Abdi
Journal:  Med Oncol       Date:  2022-05-17       Impact factor: 3.064

3.  Carnosol Is a Novel Inhibitor of p300 Acetyltransferase in Breast Cancer.

Authors:  Halima Alsamri; Hussain El Hasasna; Bincy Baby; Aysha Alneyadi; Yusra Al Dhaheri; Mohammed Akli Ayoub; Ali H Eid; Ranjit Vijayan; Rabah Iratni
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

4.  BPTF promotes tumor growth and predicts poor prognosis in lung adenocarcinomas.

Authors:  Meng Dai; Jian-Jun Lu; Wei Guo; Wendan Yu; Qimin Wang; Ranran Tang; Zhipeng Tang; Yao Xiao; Zhenglin Li; Wei Sun; Xiuna Sun; Yu Qin; Wenlin Huang; Wu-guo Deng; Taihua Wu
Journal:  Oncotarget       Date:  2015-10-20

5.  A new avenue for obtaining insight into the functional characteristics of long noncoding RNAs associated with estrogen receptor signaling.

Authors:  Liangcai Wu; Qianqian Xu; Haohai Zhang; Ming Li; Chengpei Zhu; Minjie Jiang; Xinting Sang; Yi Zhao; Qiang Sun; Haitao Zhao
Journal:  Sci Rep       Date:  2016-08-19       Impact factor: 4.379

6.  P300 promotes migration, invasion and epithelial-mesenchymal transition in a nasopharyngeal carcinoma cell line.

Authors:  Zhi-Wei Liao; Lei Zhao; Mu-Yan Cai; Mian Xi; Li-Ru He; Fang Yu; Tong-Chong Zhou; Meng-Zhong Liu
Journal:  Oncol Lett       Date:  2016-12-13       Impact factor: 2.967

7.  KAT3B-p300 and H3AcK18/H3AcK14 levels are prognostic markers for kidney ccRCC tumor aggressiveness and target of KAT inhibitor CPTH2.

Authors:  Elisa Cocco; Manuela Leo; Claudia Canzonetta; Serena Di Vito; Antonello Mai; Dante Rotili; Arianna Di Napoli; Andrea Vecchione; Cosimo De Nunzio; Patrizia Filetici; Antonella Stoppacciaro
Journal:  Clin Epigenetics       Date:  2018-04-04       Impact factor: 6.551

8.  Antitumoral and antimetastatic activity of Maitake D-Fraction in triple-negative breast cancer cells.

Authors:  Eliana Noelia Alonso; María Julia Ferronato; María Eugenia Fermento; Norberto Ariel Gandini; Alejandro López Romero; Josefina Alejandra Guevara; María Marta Facchinetti; Alejandro Carlos Curino
Journal:  Oncotarget       Date:  2018-05-04

9.  EP300 as an oncogene correlates with poor prognosis in esophageal squamous carcinoma.

Authors:  Yanghui Bi; Pengzhou Kong; Ling Zhang; Heyang Cui; Xiaoqin Xu; Feiyun Chang; Ting Yan; Jiayi Li; Caixia Cheng; Bin Song; Xia Niu; Xiangchen Liu; Xue Liu; Enwei Xu; Xiaoling Hu; Yu Qian; Fang Wang; Hongyi Li; Yanchun Ma; Jian Yang; Yiqian Liu; Yuanfang Zhai; Yi Wang; Yingchun Zhang; Haiyan Liu; Jing Liu; Jintao Wang; Yongping Cui; Xiaolong Cheng
Journal:  J Cancer       Date:  2019-08-29       Impact factor: 4.207

Review 10.  Targeting Histone Modifications in Bone and Lung Metastatic Cancers.

Authors:  Courtney M Edwards; Rachelle W Johnson
Journal:  Curr Osteoporos Rep       Date:  2021-03-15       Impact factor: 5.163

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.